Buchumschlag

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	A. B. Fons, P. W. J. Maljaars
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
von: A. B. Fons, et al.
Veröffentlicht: (2026)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
von: Chang Liu, et al.
Veröffentlicht: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
von: Isabel Carbery, et al.
Veröffentlicht: (2024)

Frailty Is Associated With All‐Cause and Acute Hospitalisations During 18 Months Follow‐Up in Older Patients With Inflammatory Bowel Disease
von: Anne B. Fons, et al.
Veröffentlicht: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
von: Sanjay K. Murthy
Veröffentlicht: (2026)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
von: Fai Fai Ho, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
von: Bharati Kochar, et al.
Veröffentlicht: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
von: Cong Dai, et al.
Veröffentlicht: (2024)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
von: Cristina Rubín de Célix, et al.
Veröffentlicht: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
von: Christian Labenz, et al.
Veröffentlicht: (2026)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
von: Anupam Kumar Singh, et al.
Veröffentlicht: (2026)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
von: Aurelien Amiot, et al.
Veröffentlicht: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
von: Mathieu Uzzan, et al.
Veröffentlicht: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
von: Catherine Z. Tang, et al.
Veröffentlicht: (2025)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
von: Monica E. W. Derks, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
von: Tamar Schildkraut, et al.
Veröffentlicht: (2024)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
von: Brigida Barberio, et al.
Veröffentlicht: (2026)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
von: J. M. Schattenberg, et al.
Veröffentlicht: (2026)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
von: Nathan Grellier, et al.
Veröffentlicht: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
von: Ryan Yanzhe Lim, et al.
Veröffentlicht: (2026)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
von: Dhruv Ahuja, et al.
Veröffentlicht: (2025)

Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
von: Walter W. Chan, et al.
Veröffentlicht: (2026)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
von: Liang Jiao, et al.
Veröffentlicht: (2026)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
von: Jeffrey D. McCurdy, et al.
Veröffentlicht: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
von: Pinelopi Arvaniti, et al.
Veröffentlicht: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
von: Juan Macias, et al.
Veröffentlicht: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
von: Lukas Burghart, et al.
Veröffentlicht: (2026)

Letter: From Descriptive Epidemiology to Clinical Imperative—Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease
von: DuJiang Yang, et al.
Veröffentlicht: (2025)

Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk
von: Saad Khan, et al.
Veröffentlicht: (2024)